Loading...
•
Jun 30, 2022
Orthofix Q2 2022 Earnings Report
Orthofix's second quarter results reflected double-digit growth in global orthopedics and progress in innovation initiatives, offset by macro headwinds and currency fluctuations.
Key Takeaways
Orthofix reported Q2 2022 net sales of $118.1 million, a decrease of 3% on a reported basis but flat on a constant currency basis. GAAP EPS was $0.12, and adjusted EPS was $0.08. The company is maintaining full-year revenue guidance of $455 to $465 million.
Net sales decreased by 3% on a reported basis but were flat on a constant currency basis compared to the prior year.
Global Orthopedics net sales grew by 11% on a constant currency basis, driven by new products and channel investments.
GAAP EPS was $0.12, and adjusted EPS was $0.08.
The company executed a partnership with CGBio to commercialize Novosis™ rhBMP-2 growth factor in the U.S. and Canada.
Orthofix
Orthofix
Orthofix Revenue by Segment
Revenue by Segment
Bone Growth Therapies Revenue
CapyFin.comSpinal Implants, Biologics and Enabling Technologies Revenue
CapyFin.comGlobal Spine Revenue
CapyFin.comGlobal Orthopedics Revenue
CapyFin.com Forward Guidance
The Company expects full year net sales to be in the range of $455 to $465 million, representing flat to 2% growth on a constant currency basis. Full year adjusted EBITDA is expected to be $53 to $57 million, and adjusted EPS is expected to be $0.45 to $0.55.
Positive Outlook
- Full year net sales growth rates – constant currency 0% - 2%
- Full year adjusted EBITDA $53 - $57
- Full year adjusted EBITDA as percentage of net sales 12%
- Full year adjusted EPS $0.45-$0.55
Challenges Ahead
- Full year net sales $455 - $465
- Full year net sales growth rates – reported (2%) - 0%
Revenue & Expenses
Visualization of income flow from segment revenue to net income